<DistDoc action="rep" dist="dist_id" distdocver="05.1" an="WSJO000020180328ee3s000xd" doctype="article"><SelectData><FolderName id="302210958" rl="100">WSJ</FolderName></SelectData><ReplyItem lang="en"><BaseLang value="en" fid="la"/><IPDocId fid="id">A7D18C4AE5094C047ED2FD784D920801 SB12621468396905554894704584129080049983924</IPDocId><AccessionNo value="WSJO000020180328ee3s000xd" fid="an"/><Num value="1006" fid="wc"/><Date value="20180328" fid="pd"/><Time value="194500" fid="et"/><SrcCode value="wsjo" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><TruncRules><XS value="29"/><S value="57"/><M value="77"/></TruncRules><Title fid="hl"><SectionName fid="se">Business</SectionName><ColumnName fid="clm"></ColumnName><Headline fid="hd"><Para lang="en">Takeda Mulls Bid for Shire to Create Global Drug Titan; A bid would represent the Japanese firm's biggest-ever deal</Para></Headline></Title><Snippet><Para>Takeda Pharmaceutical Co.'s potential pursuit of Shire PLC would rank as one of the biggest-ever attempts by a Japanese company to take over a Western rival, as a strengthening yen helps fuel ambitious overseas expansion.</Para></Snippet><Byline fid="by">By Peter Landers in Tokyo and Noemie Bisserbe in Paris </Byline><Credit fid="cr"></Credit><Copyright fid="cy">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright><CodeSets><CSet fid="co"><Code value="shiph"/><Code value="tkdci"/><Code value="glxo"/></CSet><CSet fid="in"><Code value="i257"/><Code value="i951"/></CSet><CSet fid="re"><Code value="jap"/><Code value="usa"/><Code value="asiaz"/><Code value="easiaz"/><Code value="eecz"/><Code value="eurz"/><Code value="namz"/><Code value="pacisz"/><Code value="puri"/><Code value="uk"/><Code value="weurz"/><Code value="apacz"/><Code value="ausnz"/><Code value="caribz"/><Code value="lamz"/></CSet><CSet fid="ns"><Code value="c181"/><Code value="c312"/><Code value="cactio"/><Code value="cadr"/><Code value="ccat"/><Code value="ciexp"/><Code value="gadhd"/><Code value="gcat"/><Code value="ghea"/><Code value="m14"/><Code value="nttwn"/><Code value="cacqu"/><Code value="cmerg"/><Code value="c17"/><Code value="c171"/><Code value="c18"/><Code value="c24"/><Code value="cdom"/><Code value="cprdop"/><Code value="gmed"/><Code value="gment"/><Code value="mcat"/><Code value="ncat"/><Code value="ndj"/><Code value="nfact"/><Code value="nfce"/><Code value="nfcpin"/><Code value="ntop"/><Code value="redit"/></CSet></CodeSets></ReplyItem><MetadataPT><DocData><DocType value="article" fid="fmt"/><IPDocId fid="id">A7D18C4AE5094C047ED2FD784D920801 SB12621468396905554894704584129080049983924</IPDocId><AccessionNo value="WSJO000020180328ee3s000xd" fid="an"/><Num value="1006" fid="wc"/><Num value="4815" fid="cc"/><Date value="20180328" fid="pd"/><Date value="20180328" fid="upd"/><Date value="20180328" fid="md"/><Time value="194500" fid="et"/><Time value="095729" fid="upt"/><Time value="194529" fid="mt"/><BaseLang value="en" fid="la"/><Editor value="" fid="rve"/><RevisionNo value="16" fid="rvn"/></DocData><PubData><Restrictor fid="rst"><Code value="FSPNORMAWS0300"/><Code value="WSJO"/><Code value="fspFileId278184429"/><Code value="FUT"/><Code value="CLNTALL"/><Code value="CTGSMFS"/><Code value="CTGWSJ"/><Code value="DEEPWSJP"/><Code value="EN"/><Code value="IBNK"/><Code value="IFINAL"/><Code value="IINV"/><Code value="NAMZ"/><Code value="SFWSJ"/><Code value="TBAC"/><Code value="TBED"/><Code value="TBIZ"/><Code value="TBRK"/><Code value="TDJP"/><Code value="TDJWMNP"/><Code value="TFCDLIC"/><Code value="TFIN"/><Code value="TIAS"/><Code value="TIBMNB"/><Code value="TIMG"/><Code value="TINT"/><Code value="TIOP"/><Code value="TMNB"/><Code value="TMNBUS"/><Code value="TNPS"/><Code value="TNWP"/><Code value="TNWPN"/><Code value="TOPUSA"/><Code value="TSCH"/><Code value="TTRD"/><Code value="TTRK"/><Code value="TUSN"/><Code value="TWMSA"/><Code value="TYAS"/><Code value="TYLA"/><Code value="USA"/><Code value="fspWebpage"/><Code value="MPCV1M9M1B1"/><Code value="MPCEnvPROD"/><Code value="MPCDocHash17803DC142081C8F"/><Code value="FSPTHINGFINDER"/><Code value="FSP2YESCO"/><Code value="FSP2YESCOCOM"/><Code value="FSPRBC"/><Code value="FSPRBCCO"/><Code value="FSPRBCCOM"/><Code value="FSP2YESCOOC"/><Code value="FSP2YESCOCOMOC"/><Code value="FSPRBCIN"/><Code value="FSP2YESIN"/><Code value="FSPRBCNS"/><Code value="FSP2YESNS"/><Code value="FSPCATEGORIZER"/><Code value="FSPCATRE"/><Code value="FSPRBCRE"/><Code value="FSP2YESRE"/><Code value="FSP2YESPEOC"/><Code value="FSPRBC41119"/><Code value="FSPRBC621588"/><Code value="FSPRBC648020"/><Code value="FSPRBC670911"/><Code value="FSPRBC703397"/><Code value="FSPRBC798520"/><Code value="FSPRBC798521"/><Code value="FSPRBC802083"/><Code value="FSPRBC802123"/><Code value="FSPRBC803818"/><Code value="FSPRBC803828"/><Code value="FSPRBC811387"/><Code value="FSPRBC829490"/><Code value="FSPRBC831087"/><Code value="FSPRBC831127"/><Code value="FSPRBC831148"/><Code value="FSPRBC849496"/><Code value="FSPRBC849536"/><Code value="FSPRBC849556"/><Code value="FSPRBC849566"/><Code value="FSPRBC852032"/><Code value="FSPRBC857604"/><Code value="FSPRBC857605"/><Code value="FSPRBC857613"/><Code value="FSPRBC857614"/><Code value="FSPRBC857619"/><Code value="FSPRBC857620"/><Code value="FSPRBC857647"/><Code value="FSPRBC857648"/><Code value="FSPRBC857716"/><Code value="FSPRBC860206"/><Code value="FSPRBC860219"/><Code value="FSPRBC860225"/><Code value="FSPRBC860298"/><Code value="FSPRBC860312"/><Code value="FSPRBC860440"/><Code value="FSPRBC860442"/><Code value="FSPRBC860461"/><Code value="FSPRBC861005"/><Code value="FSPRBC861175"/><Code value="FSPRBC861176"/><Code value="FSPRBC861199"/><Code value="FSPRBC861321"/><Code value="FSPRBC861461"/><Code value="FSPRBC861482"/><Code value="FSPRBC861517"/><Code value="FSPRBC861686"/><Code value="FSPRBC861689"/><Code value="FSPRBC861762"/><Code value="FSPRBC861811"/><Code value="FSPRBC861918"/><Code value="FSPRBC864383"/><Code value="FSPRBC876146"/><Code value="MPCCL"/><Code value="MPCJP"/><Code value="MPCKW"/><Code value="MPCKP"/><Code value="MPCESRE"/><Code value="MPCESIN"/><Code value="MPCESNS"/><Code value="FSP2AC"/></Restrictor><IPId value="DJENT" fid="ip"/><PublisherN fid="pub">Dow Jones &amp; Company, Inc.</PublisherN><AttribCode value="WSJO2" fid="atr"/><SrcCode value="WSJO" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><Logo img="wsjoLogo.gif" link="" src="http://logos.factiva.com"/></PubData><CodeSets><CSet fid="co"><Code value="shiph"><CodeD index="no" lang="en">Shire PLC</CodeD><CodeI org="thingfinder" action="add"><CodeA name="db" value="ptf--aboutCo-00004107-20180322-231424.dictionary"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="tkdci"><CodeD index="no" lang="en">Takeda Pharmaceutical Company Limited</CodeD><CodeI org="thingfinder" action="add"><CodeA name="db" value="ptf--aboutCo-00004107-20180322-231424.dictionary"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="670911"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="703397"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="glxo"><CodeD index="no" lang="en">GlaxoSmithKline PLC</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="41119"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code></CSet><CSet fid="in"><Code value="i257"><CodeD index="no" lang="en">Pharmaceuticals</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861811"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="648020"/><CodeA name="rule" value="802123"/><CodeA name="rule" value="831127"/><CodeA name="rule" value="849536"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="co:shiph"/><CodeA name="root" value="co:tkdci"/><CodeA name="root" value="co:glxo"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="i951"><CodeD index="no" lang="en">Health Care/Life Sciences</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861918"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="in:i257"/><CodeA name="root" value="in:i257"/><CodeA name="root" value="in:i257"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet><CSet fid="re"><Code value="jap"><CodeD index="no" lang="en">Japan</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishRE_en_20180319142019"/><CodeA name="es_score" value="90"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="861321"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="621588"/><CodeA name="rule" value="857614"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="usa"><CodeD index="no" lang="en">United States</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishRE_en_20180319142019"/><CodeA name="es_score" value="88"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="861689"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="803828"/><CodeA name="rule" value="849566"/><CodeA name="rule" value="857716"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="asiaz"><CodeD index="no" lang="en">Asia</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861005"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="857604"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:jap"/><CodeA name="root" value="re:easiaz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="easiaz"><CodeD index="no" lang="en">Eastern Asia</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861199"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:jap"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="eecz"><CodeD index="no" lang="en">European Union Countries</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861176"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:uk"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="eurz"><CodeD index="no" lang="en">Europe</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="811387"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="829490"/><CodeA name="rule" value="861175"/><CodeA name="rule" value="857648"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:eecz"/><CodeA name="root" value="re:uk"/><CodeA name="root" value="re:weurz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="namz"><CodeD index="no" lang="en">North America</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861461"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:usa"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="pacisz"><CodeD index="no" lang="en">Pacific Islands</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861482"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="puri"><CodeD index="no" lang="en">Puerto Rico</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861517"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="uk"><CodeD index="no" lang="en">United Kingdom</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861686"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="857620"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="weurz"><CodeD index="no" lang="en">Western Europe</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861762"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:uk"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="apacz"><CodeD index="no" lang="en">Asia Pacific</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:jap"/><CodeA name="root" value="re:easiaz"/><CodeA name="root" value="re:pacisz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ausnz"><CodeD index="no" lang="en">Australia/Oceania</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:pacisz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="caribz"><CodeD index="no" lang="en">Caribbean Islands</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:puri"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="lamz"><CodeD index="no" lang="en">Latin America</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:puri"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet><CSet fid="ns"><Code value="c181"><CodeD index="no" lang="en">Acquisitions/Mergers/Shareholdings</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860440"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="c312"><CodeD index="no" lang="en">Corporate/Industry Exports</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="864383"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="cactio"><CodeD index="no" lang="en">Corporate Actions</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860206"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:cadr"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="cadr"><CodeD index="no" lang="en">American Depository Receipts</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860461"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="ccat"><CodeD index="no" lang="en">Corporate/Industrial News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860225"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="831148"/><CodeA name="rule" value="857605"/><CodeA name="rule" value="857613"/><CodeA name="rule" value="857619"/><CodeA name="rule" value="857647"/><CodeA name="rule" value="803818"/><CodeA name="rule" value="849556"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:c312"/><CodeA name="root" value="ns:cactio"/><CodeA name="root" value="ns:cadr"/><CodeA name="root" value="ns:ciexp"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ciexp"><CodeD index="no" lang="en">International Expansion (Facilities)</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="876146"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="gadhd"><CodeD index="no" lang="en">Neurodevelopmental Disorders</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="852032"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="4"/></CodeI></Code><Code value="gcat"><CodeD index="no" lang="en">Political/General News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860298"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:gadhd"/><CodeA name="root" value="ns:ghea"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ghea"><CodeD index="no" lang="en">Health</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860312"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:gadhd"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="m14"><CodeD index="no" lang="en">Commodity Markets</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860219"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="nttwn"><CodeD index="no" lang="en">Today's Top Wire News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860442"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="cacqu"><CodeD index="no" lang="en">Acquisitions/Mergers</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="798521"/><CodeA name="db" value="prbc---00018595-20180328-074858"/><CodeA name="rule" value="802083"/><CodeA name="rule" value="831087"/><CodeA name="rule" value="849496"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="3"/><CodeA name="nodelevel" value="4"/></CodeI></Code><Code value="cmerg"><CodeD index="no" lang="en">Mergers</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="798520"/><CodeA name="db" value="prbc---00018595-20180328-074858"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="4"/><CodeA name="nodelevel" value="5"/></CodeI></Code><Code value="c17"><CodeD index="no" lang="en">Corporate Funding</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:cadr"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c171"><CodeD index="no" lang="en">Share Capital</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:cadr"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="c18"><CodeD index="no" lang="en">Ownership Changes</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="c24"><CodeD index="no" lang="en">Capacity/Facilities</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:ciexp"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="cdom"><CodeD index="no" lang="en">Domestic/Foreign Markets</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c312"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="cprdop"><CodeD index="no" lang="en">Facility Openings</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:ciexp"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="gmed"><CodeD index="no" lang="en">Medical Conditions</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:gadhd"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="gment"><CodeD index="no" lang="en">Mental Disorders</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:gadhd"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="mcat"><CodeD index="no" lang="en">Commodity/Financial Market News</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:m14"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ncat"><CodeD index="no" lang="en">Content Types</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:cadr"/><CodeA name="root" value="ns:m14"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="ndj"><CodeD index="no" lang="en">Dow Jones Top Stories</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:nttwn"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="nfact"><CodeD index="no" lang="en">Factiva Filters</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:cadr"/><CodeA name="root" value="ns:m14"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfce"><CodeD index="no" lang="en">C&amp;E Exclusion Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:m14"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfcpin"><CodeD index="no" lang="en">C&amp;E Industry News Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:cadr"/><CodeA name="root" value="ns:cacqu"/><CodeA name="root" value="ns:cmerg"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="ntop"><CodeD index="no" lang="en">Top Wire News</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:nttwn"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="redit"><CodeD index="no" lang="en">Selection of Top Stories/Trends/Analysis</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:nttwn"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet></CodeSets><DescTPC fid="de"><DescField fid="ipc">4502.TO ABBV GSK GSK.LN I/DRG I/X225 I/XATI I/XDJGI I/XEX6 I/XFT1 I/XGDW I/XHCT I/XISL I/XNQ1 I/XSLI JE00B2QKY057 JP3463000004 M/HCR M/NND N/ADR N/AER N/APIN N/BKG N/CAC N/CMDI N/CNW N/DJAE N/DJEI N/DJEP N/DJG N/DJG7 N/DJGP N/DJGS N/DJGV N/DJI N/DJIV N/DJN N/DJPN N/DJPT N/DJQA N/DJQS N/DJWI N/DN N/ECR N/EUCM N/EWR N/FXW N/GEN N/HLT N/MADN N/NJR N/TNM N/TNW N/TSY N/UKMR N/WED N/WEI N/WER N/WSJC NOVN.EB NVS P/ABO P/AEI P/AEQ P/AEQI P/AFXI P/BCL P/EWR P/MABA P/MC1 P/SGN P/SIC P/WMMI R/ASI R/EC R/EU R/FE R/FEO R/JA R/NME R/PRM R/UK R/US R/WEU SAN.FR SHP.LN SHPG SNY TKPYY US82481R1068 US8740602052 </DescField><DescField fid="ipd">NWREGULAR WSJ WSJ.com WSJ.com Site Search WSJAsia WSJEurope WSJ Japanese Online WSJ-PRO-WSJ.com WSJSunday DRUGS M&amp;A SHIRE TAKEDA SB126214683969055548947045841290800499839247 Kubota, Masayuki Ornskov, Flemming SYND CODES_REVIEWED Wires Business </DescField><DescField fid="ipcns">OASI OBIJ OBUK OEUR OUSB </DescField><DescField fid="ipcconame">Takeda Pharmaceutical </DescField><DescField fid="ipccodj">4502.TO ABBV </DescField></DescTPC></MetadataPT><ArchiveDoc xml:space="preserve"><Article markup="pp0" lang="en" index="field"><HandL fid="hlp"><Title fid="hl"><SectionName fid="se" index="field">Business</SectionName><ColumnName fid="clm" index="field"></ColumnName><Headline fid="hd"><Para lang="en">Takeda Mulls Bid for Shire to Create Global Drug Titan; A bid would represent the Japanese firm's biggest-ever deal</Para></Headline></Title><LeadPara fid="lp"><Para>Takeda Pharmaceutical Co.'s potential pursuit of Shire PLC would rank as one of the biggest-ever attempts by a Japanese company to take over a Western rival, as a strengthening yen helps fuel ambitious overseas expansion.</Para><Para>Takeda said Wednesday it is weighing a bid for London-listed Shire, whose drugs include Adderall, for attention deficit hyperactivity disorder. The potential deal would create a global drug giant worth nearly $90 billion and add to a torrid run for mergers and acquisitions so far this year—much of it in health care as companies in the industry respond to a rapidly changing landscape.</Para></LeadPara></HandL><TailParas fid="td"><Para>A bid would represent Takeda's biggest-ever deal, capping a string of smaller acquisitions in recent years aimed at broadening its international footprint. Takeda, founded in 1781 and Japan's largest drugmaker by revenue and market capitalization, needs to keep expanding overseas to make up for a slowing market at home, analysts said.</Para><Para>If Takeda did nothing, "they'd only be waiting to die," said Masayuki Kubota, chief strategist Rakuten Securities in Tokyo.</Para><Para>Shares of Shire gained 14% on Wednesday following the disclosure, boosting its market value to £32 billion, or about $45 billion—higher than Takeda's $42 billion value at the close of Tokyo trading Wednesday.</Para><Para>The recent rise in the yen, to its highest level against the dollar since November 2016, provides a tailwind for Japanese companies looking to boost their global presence. The yen they earn at home can now buy more in dollars or pounds than just a year ago.</Para><Para>Takeda described its interest in Shire as "preliminary and exploratory." Yet it laid out an aggressive case for a deal, listing six motivations, including bolstering its position in the U.S. pharmaceutical market and replenishing its drug pipeline.</Para><Para>Shire's group headquarters are in Ireland, and it runs its U.S. business—which accounts for about two-thirds of total sales—out of Lexington, Mass.</Para><Para>Though best-known in the U.S. for Adderall, the company has more recently developed into one of the world's biggest makers of drugs for rare diseases, expanding quickly under the leadership of Chief Executive Flemming Ornskov.</Para><Para>In a statement Shire said it had noted Takeda's disclosure but confirmed no approach had been made, adding there was no certainty an offer would ensue. Takeda said that under U.K. takeover rules, it must announce by April 25 whether it intends to make an offer for Shire.</Para><Para>News of Takeda's interest came just a day after GlaxoSmithKline PLC said it would pay Novartis AG $13 billion for its 36.5% stake in their consumer health-care joint venture. In January, France's Sanofi SA said it would buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion.</Para><Para>Merger-and-acquisition volume is up about 50% in the U.S. and globally compared with last year, according to Dealogic, as strong stock prices and tax-law changes encourage acquirers.</Para><Para>Technology has been the busiest sector for deals, with $168 billion struck so far in 2018, followed by health care at $149 billion. In the biggest takeover announced so far this year, health insurer Cigna Corp. this month agreed to buy pharmacy-benefits manager Express Scripts Holding Co. for about $54 billion.</Para><Para>Shire has regularly been involved in deal talks in recent years.</Para><Para>In 2014, <ELink type="webpage" ref="https://www.wsj.com/articles/abbvie-shire-terminate-what-was-years-biggest-deal-1413841225">a $54 billion takeover</ELink> of Shire by Illinois-based AbbVie Inc. was called off because of new U.S. tax rules aimed at deterring American companies from moving their legal headquarters to lower-tax countries.</Para><Para><ELink type="webpage" ref="https://www.wsj.com/articles/shires-ceo-pushed-hard-for-baxalta-deal-1452656564">In 2016, Shire paid $32 billion to acquire Baxalta Inc.</ELink>, a maker of medicines for rare blood conditions such as hemophilia, cancers and immune system disorders. Since then, its shares have fallen, and once viewed as a voracious predator, the company has been seen more recently by analysts as possible prey because of its weaker share price.</Para><Para>Takeda, whose products include the heartburn treatment Dexilant, has made several large acquisitions under its current chief executive, Frenchman Christophe Weber, and his predecessor.</Para><Para><ELink type="webpage" ref="https://www.wsj.com/articles/SB120780958090604441">Those deals include Millennium Pharmaceuticals </ELink>Inc. in 2008 and Nycomed A/S of Switzerland in 2011, which combined totaled about $23 billion. Mr. Weber, a former GlaxoSmithKline PLC executive, became Takeda's president in 2014 and added the CEO title the next year. The biggest deal under his leadership is last year's acquisition of U.S. cancer-drug maker Ariad Pharmaceuticals Inc. for about $5 billion.</Para><Para>A deal for Shire would easily outclass those deals and place Takeda among the world's biggest pharmaceutical companies, with annual revenue of more than $30 billion.</Para><Para><ELink type="webpage" ref="https://www.wsj.com/articles/takeda-pharmaceutical-prescribes-stability-after-rough-start-1504608028">In an interview last September</ELink>, Mr. Weber was cautious about new deals, citing a sharp rise in Takeda's debt relative to its operating income after the Ariad acquisition. "We don't want to be overstretched," he said at the time. "We are very risk-aware."</Para><Para>Nonetheless, Shire's pipeline of new drugs would be attractive for Takeda at a time when it is short of potential blockbusters in development.</Para><Para>Mr. Weber has pushed to internationalize Osaka-based Takeda, which generates more than 60% of its revenue outside Japan, in part by centralizing much of the company's research in the Boston area, where Millennium was based. A combination with Shire's nearby U.S. base could enable cost savings.</Para><Para>Takeda disclosed its interest on Wednesday morning in London, after Shire shares jumped the previous day, closing up 4%.</Para><Para>Kosaku Narioka and Adam Clark contributed to this article.</Para><Para>Write to Peter Landers at <ELink type="webpage" ref="mailto:peter.landers@wsj.com">peter.landers@wsj.com</ELink> and Noemie Bisserbe at <ELink type="webpage" ref="mailto:noemie.bisserbe@wsj.com">noemie.bisserbe@wsj.com</ELink></Para><Para>Related</Para><Para>* <ELink type="webpage" ref="https://www.wsj.com/articles/gsk-to-buy-out-novartiss-stake-in-health-care-venture-for-13-billion-1522130448">GSK Buys Novartis's Stake in Health-Care Unit for $13 Billion</ELink> (March 27)</Para><Para>* <ELink type="webpage" ref="https://www.wsj.com/articles/sanofi-nears-deal-to-buy-hemophilia-drugmaker-bioverativ-for-more-than-11-5-billion-1516584141">Sanofi to Buy Hemophilia Drugmaker Bioverativ for Over $11.5 Billion</ELink> (Jan. 22)</Para><Para>* <ELink type="webpage" ref="https://www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153">Celgene to Buy Juno Therapeutics for $9 Billion</ELink> (Jan. 22)</Para></TailParas><Byline fid="by" index="field">By Peter Landers in Tokyo and Noemie Bisserbe in Paris </Byline><Credit fid="cr" index="field"></Credit><Contact fid="ct" index="field"></Contact><Notes fid="rf" index="field"></Notes><Art fid="art" index="field"></Art><Copyright fid="cy" index="field">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright></Article></ArchiveDoc><AdocTOC adoctype="article"><Item size="0" ref="distdoc:archive/ArchiveDoc::Article" type="arttext"></Item><Item size="0" ref="distdoc:archive/InvertText" type="invtext"></Item><Item subtype="primary" size="0" ref="https://www.wsj.com/articles/takeda-mulls-bid-for-pharma-rival-shire-1522231040" type="webpage"></Item></AdocTOC></DistDoc>

